

REFERENCES

REFERENCES

- **Aisner SC and Mathews MJ (1985):**
The pathology of lung cancer. In: Lung cancer.
Aisner J (ed) Churchill Livingstone, New York.
p.211.
- **Akoun GM, Scavna HM, Millerom BH,
Benichonn MR and Herman DP (1985):**
Serum neuron specific enolase; a marker for dis-
extent and response to therapy for small cell lung
cancer.
Chest, 87:39.
- **Alderson PO (1986):**
Scintigraphic evaluation of patients with lung
cancer.
Chest, 89 (4): 2458.
- **American Joint Committee on cancer (Ajcc)
(1992):**
Lung in manual for staging of cancer. 4th ed.
Bearhsoh et al. (editor) Lippincott.
- **Austin LA and Health H (1981):**
Calcitonin: Physiology and pathophysiology.
N. Engl. J. Med., 304:269.

- **Bacchus H (1977):**
Serum glycoproteins and malignant neoplastic disorder.
Crit. Rev. Clin. Lab. Sci., 8:333.
- **Bach F, Soetormos G, Bach FW and Pedersen AG (1990):**
TPA and CK-BB: new tumour markers in leptomeningeal carcinomatosis secondary to breast cancer (letter):
J. Natl. Cancer Inst., 82(4):320.
- **Bach F, Soletormos G and Dombernowsky P (1991):**
Tissue polypeptide antigen activity in cerebrospinal fluid: a marker of central nervous system metastases of breast cancer.
J. Natl. Cancer Inst., 83(11):779.
- **Bagschawe (1983):**
Tumour markers, where do we go from here.
Cancer, 48:176.
- **Bahr J, Carlsson K and Luning B (1988):**
An epitope in coil 2B of cytokeratin 8.
Acta. Chem. Scand., B42:442.

- **Band PR, Feldestin M and Saccomano G (1986):**
Reversibility of bronchial marked atypia:
Implication of chemoprevention.
Cancer Detect. Prevent., 9:157.
- **Bartter FC and Schwartz WB (1967) Quoted from Clinical Chemistry (1994):**
The syndrome of inappropriate secretion of ADH.
Am. J. Med., 42:790.
- **Bates J, Rotherford R, Divilly M, Finn J and Grimes H (1998):**
Clinical value of CYFRA21-1, CEA, NSE, TPS and TPA in diagnosis of lung cancer.
Eur. Respir. J., 10:2535.
- **Bates SE and Longo DL (1989):**
Uses of serum tumour markers in cancer diagnosis and management.
Semin Oncol., 14:102.
- **Bates SE (1991):**
Clinical applications of serum tumour markers.
Ann. Int. Med., 115:623.

- **Bates SE and Longo DL (1985):**
Tumour markers value and limitations in the management of cancer patients.
Cancer Treat. Rev., 12:163.
- **Becker KL, Monaghan KG and Silva OL (1980):**
Immunocytochemical localization of calcitonin in Kultschitzky cells of human lung.
Arch Pathol. Lab. Med., 104:196.
- **Benbasset J, Regev A and Stater PE (1987):**
Predictive value of sputum cytology.
Thorax, 42:165.
- **Benjamin N, Norman H, Mario B, Tamar P and Vivian B (1998):**
Evaluation of tissue polypeptide specific antigen, CYFRA21-1 and CEA in non small cell lung cancer.
Cancer, 82:1850.
- **Bergman B, Brezicka FT and Engstrom CP (1993):**
clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis.
Eur. J. Cancer, 29A:198.

- **Birkmayer GTD (1988):**
Tumour markers in diagnosis and therapy of cancer preceeding of the 1st International Conference on Tumour Markers.
The Egyptian Society of Tumour Marker Oncology.
- **Bjorklund B (1980):**
On the nature and clinical use of tissue polypeptide antigen (TPA).
Tumour Diagnostic, 1:9.
- **Bjorklund B (1957) Quoted from Clinical Chemistry (1994):**
Effect of horse anti-human cancer serum on malignant and normal human cells.
Int. Arch. Allergy 10(1):56.
- **Bjorklund B (1978):**
Tissue polypeptide antigen (TPA): biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions and future outlook.
Antibiot. Chemother., 22:61.

- **Bjorklund B (1980):**
On the nature and clinical use of tissue polypeptide antigen (TPA).
Tumour Diagnostic, 1(1):9.
- **Bjorklund B (1981):**
Tissue polypeptide antigen: Review and recent progress. Contr.
Oncol., 7:73.
- **Bjorklund V (1982):**
Differential immunocytochemical localization of TPA and CEA in breast cancer.
Cancer Detect Prev., 5(2): 247.
- **Bjorklund B (1992):**
Letters to the editor: Tumour markers TPA, TPA-S and cytokeratins.
Tumour diagn. U. Ther., 13:78.
- **Bjorklund V (1987) Quoted from Clinical Chemistry (1994):**
Biochemical and morphological basis for TPA. Progress towards a general marker for active tumours by monoclonal mapping. In: Tumour marker system CEA-TPA. Basis, Methodology, Clinical Concordance. Edited by: Luthgens M. and Schlegel G (eds). Leonberg, Germany.
Tumour Diagnostic, Verlag, 14.

- **Bjorklund V, Bjorklund B, Wittekind C and Von Kleist S (1982):**
Immunohistochemical localization of TPA and CEA in breast cancer. A comparative study.
Acta. Pathol. Microbiol. Immunol. Scand. A., 90(6): 471.
- **Blasco R, Barbero EM, Munoz C and Gomez de Terreros F (1989):**
TPA in bronchoalveolar lavage.
Int. J. Biol. Markers, 4(2):119.
- **Bloomfield GA, Holdway JM and Corrin B (1977):**
Lung tumours and ACTH production.
Clin Endocrinol., 6:95.
- **Bodenmuller H (1993):**
Symposium cytokeratins and tissue polypeptide antigen 18, 19 March 1993, Istituto Nazionale per lo studio e la cura dei Tumori, Milano.
Int. T. Biol. Markers, 29:160.
- **Bonnen U, Oehr P, Liu Q and Biersack HG (1989):**
Tissue polypeptide antigen in patients with breast cancer, longitudinal study.
Med. Nucl., 1:355.

- **Bjorklund V, Bjorklund B, Wittekind C and Von Kleist S (1982):**
Immunohistochemical localization of TPA and CEA in breast cancer. A comparative study.
Acta. Pathol. Microbiol. Immunol. Scand. A., 90(6): 471.
- **Blasco R, Barbero EM, Munoz C and Gomez de Terreros F (1989):**
TPA in bronchoalveolar lavage.
Int. J. Biol. Markers, 4(2):119.
- **Bloomfield GA, Holdway JM and Corrin B (1977):**
Lung tumours and ACTH production.
Clin Endocrinol., 6:95.
- **Bodenmuller H (1993):**
Symposium cytokeratins and tissue polypeptide antigen 18, 19 March 1993, Istituto Nazionale per lo studio e la cura dei Tumori, Milano.
Int. J. Biol. Markers, 29:160.
- **Bonnen U, Oehr P, Liu Q and Biersack HG (1989):**
Tissue polypeptide antigen in patients with breast cancer, longitudinal study.
Med. Nucl., 1:355.

- **Brincker H and Wilbek E (1984):**
The incidence of malignant tumours in patients with respiratory sarcoidosis
Br. J. Cancer, 29:247.
- **Bucceri G and Ferrigno D (1988):**
Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer.
Chest, 93:565.
- **Bucceri G and Ferrigno D (1995):**
The tissue polypeptide antigen serum test in the preoperative evaluation of non small cell lung cancer. Diagnostic yield and comparison with conventional staging methods.
Chest, 107(2):471.
- **Buccheri GF, Biolante B, Sartoris AM and Ferrigno D (1986):**
Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma.
Cancer, 57:2389.

- **Buccheri GF, Ferrigno D and Sartoris AM (1987):**
Tumour markers in bronchogenic carcinoma.
Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinants, 19:9.
Cancer, 60:42.
- **Buccheri GF and Ferrigno D (1988):**
Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer.
Chest, 93:585.
- **Campling BG, Sarda IR and Baer KA (1995):**
Secretion of atrial peptide and vasopressin by small cell lung cancer.
Cancer, 75:2442.
- **Carbin BE, Collins VP and Ekman P (1987):**
Tissue polypeptide antigen (TPA), some cytokeratins and epithelial membrane antigen (EMA) in normal, inflamed and malignant urothelium.
Urol. Res. 15(4):191.

- **Carfinkel L and Stellman SD (1988):**
Smoking and lung cancer in women findings in prospective study.
Cancer Res., 48:6951.
- **Carl A and Edward R (1996):**
Tietz Fundamentals of clin. Chemistry.
p. 144.
- **Carney DN and Leij LD (1988):**
Lung cancer biology. Semin.
Oncol., 15:199.
- **Castle WN (1977):**
Basic statistics. In: Statistics in small dose, 2nd ed, Castle WN (ed.) Churchill Livingstone, Edinburgh, London, New York, P. 120.
- **Chan DW and Sell S (1994):**
Tumour markers. In: Burtis CA and Ashwood (eds.). Teitz Textbook of Clinical Chemistry, 2nd ed. vol. 2, Ed. by Saunders Company, W.B., p.897.
- **Clee MD and Sinclair DJM (1981):**
Assessment of factors influencing the results of sputum cytology in bronchial carcinoma.
Thorax, 36:143.

- **Cohen MH (1977):**
Signs and symptoms of bronchogenic carcinoma. In: Straus MJ (ed.).
Lung cancer: Clinical diagnosis and treatment.
pp.85. New York, Grune, Stratton.
- **Collazos J, Genolla J and Ruibal A (1993):**
A clinical and biochemical study on tissue polypeptide antigen (TPA) in non malignant hepatic disorders.
Scand. J. Clin. Lab. Invest., 53(6):633.
- **Coolen RB, Pragay DA and Nosanchuck JS (1979):**
Elevation of brain type creatinine kinase in serum from patients with carcinoma.
Cancer, 44:1414.
- **Coughlen M, Deslauriers J and Beaulieu M (1985):**
Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer.
Ann. Thorac. Surg., 40:556.

- **Crombach G, Zippel III, Schmidt-Rhode P and Wiirz H (1984):**
Serum levels of TPA in patients with gynecological cancer.
Prot. Biol. Fluids, 31:441.
- **Cryzboski S and Coy P (1970):**
Early diagnosis of carcinoma of lung. Simultaneous screening with chest X-ray and sputum cytology.
Cancer, 25:113.
- **Cunningham BA, Hemperly JJ and Murray BA (1987):**
Neural cell adhesion molecule: structure, Immunoglobulin-like domains, cell surface modulation and alternative RNA splicing.
Science, 236.
- **Cuttitta F, Fedorko J and Gu J (1988):**
Gastrin-releasing peptide gene-associated peptides are expressed in normal fetal lung and small cell lung cancer: a novel peptide family found in man.
J. Clin. Endocrinol. Metab., 67:576.

- **DeAngelis G, Cipri A, Flore F, Munno R, Pau F, Piagorini F (1985):**
Valutazione dei titoli plasmatici dell'antigene carcinoembrionario (CEA) e dell'antigene polipeptidico tissutale (TPA) in 158 soggetti normali e in 140 pazienti con carcinoma polmonare primitivo. Min Pneumol. p. 132.
- **DeBie SH, Ferreira TC and Pawels EK (1992):**
Immunoscintigraphy for cancer detection "A thousand ill requir thousand cures".
J. Cancer Res. Clin. Oncol., 118:1.
- **Dieksheide (1981):**
CEA assay precautions. (letter).
Diagn. Med. 4:114.
- **Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N and Bonbardierei E (1994):**
Cytokeratin 19 fragment- CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer.
Eur. J. Clin. Chem. Cli. Biochem., 32:779.

- **Ebert W, Kayser K and Buelzebruch H (1988):**
Diagnostic validity of the SCC antigen assays in squamous cell carcinoma of the lung.
J. of Tumour Marker Oncology, 3:35.
- **El-Ahmady O, Halim AB, Mansour O and Salman T (1992):**
The clinical value of TPA for cancer patients: Egyptian experiences. In: Klapdor, R. (ed) Tumour associated antigens. Oncogenes, receptors, cytokines in tumour diagnosis and therapy at the begining of the nineties. Cancer of the breast, state and trends in diagnosis and therapy.
W. Zuckschwerdt, Verlag, Munchen, Bernwien, New York.
- **Enstom JE (1979):**
Rising lung cancer mortality rate among non smokers.
J. Natl. Cancer Inst., 62:755.
- **Esscher T, Steinhdtzl and Berghj (1985):**
Neuron-specific enolase: a usefull dignostic serum marker for small cell carcinoma of the lung.
Thorax, 40:85.

- **Eugene, Braun W, Kur T, Isselbacher, Robert G, Jean D, Joseph B and Anthony S (1996):**
Harrison's principles of internal medicine.
p. 879.
- **Falcon F, Fini A and Magri P (1983):**
Dosaggio dell'antigen carcino-embrionario (CEA) plasmatico nelle pneumopatie neoplastiche non neoplastiche.
Acta Oncol., 4:173.
- **Feinstein AR, Getfman NA and Yesner R (1970):**
Observer variability in histopathologic diagnosis of lung cancer.
Am. Rev. Respir. Dis., 101:671.
- **Fishman AP (1988):**
Pathology of carcinoma of the lung. In: Pulmonary diseases and disorders.
Fourth ed. vol. III. McGraw-Hill Book Company, New York.

- **Fogiel M (1986):**
Non-parametric methods in the statistics problem solver.
2nd ed. Research and Education Association,
New York, p. 864.
- **Fontana RS, Sanderson DR and Woolner LB (1986):**
Lung cancer screening:
The Mayo program. J. Occup. Med., 28:746.
- **Frank JL, Janet LD and Michael LB (1985):**
Biochemistry of tumour markers. In:
Michel, L.B. (ed.): Clinical Chemistry:
Principles and Procedures. Lippincott Company,
Philadelphia.
- **Franke WW, Schmid E, Weber K and Osborn M (1979):**
Hela cells contain intermediate filaments of the prokeratin type.
Exp. Cell. Res., 118:95
- **Friedman GD (1983):**
Phenylbutazone, musculoskeletal disease and leukemia.
J. Chron. Dis., 35:233.

- **Friedman AS, Mallot KA and Memoli VA (1994):**
Products of vasopressin gene expression in small cell carcinoma of the lung.
Br. J. Cancer, 69:260.
- **Fuchs EV, Coppock SM, Green M and Cleveland DW (1981):**
Two distinct classes of keratin genes and their evolutionary significance.
Cell, 27:75.
- **Fukazawa I, Inaba N and Ota Y (1988):**
Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA 125) and their immunohistochemical identification in benign and malignant gynecologic disease.
Arch. Gynecol. Obstet., 243:41.
- **Gardner RC, Feinerman AE, Kantrowitz PA (1978):**
Serial (CEA) blood levels in patients with ulcerative colitis.
Am. J. Dig. Dis., 23:129.

- **Geisler N and Weber K (1982):**
The amino acid sequence of chicken muscle desmin provides a common structural model of intermediate filament proteins.
EMBO. J., 1:1649.
- **Gewirtz G and Yalow RS (1974):**
Ectopic ACTH production in carcinoma of the lung.
J. Clin. Invest., 53:1022.
- **Glazer GM, Gross BH and Aisen AM (1985):**
Imaging of pulmonary hilum: A prospective comparison study in patients with lung cancer.
Am. J. Radiol., 145:245.
- **Go VL (1976):**
Carcinoembryonic antigen. Clinical application.
Cancer, 37:562.
- **Gold P and Freedman S (1975):**
Demonstration of tumour specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques.
J. Exp. Med., 121:439.

- **Goldstraw P, Kurzer M and Edward D (1983):**
Preoperative staging of lung cancer: Accuracy of computed tomography versus mediastinoscopy.
Thorax, 38:10.
- **Goslin RH , O'Brien MJ and Skarin AT (1983):**
Immunocytochemical staining for CEA in small cell carcinoma of lung predicts clinical usefulness of the plasma assay.
Cancer, 52:301.
- **Goslin RH, Skarin AT and Zamckeck N (1981):**
Carcinoembryonic antigen: A useful monitor of therapy of small cell lung cancer.
JAMA, 246:2173.
- **Gronowitz JS, Bergstrom R and Nou E (1990):**
Clinical and serologic markers of stage and prognosis in small cell lung cancer: a multivariate analysis.
Cancer, 66:722.

- **Gu J, Linnolila PI and Seibel NC (1988):**
A study of myc-related gene expression in small cell lung cancer by in situ hybridization.
Am. J. Path., 132:13.
- **Hansen HJ, Snyder LJ and Miller E (1974):**
CEA assay. A laboratory adjunct in the diagnosis and management of cancer.
J. Hum. Pathol., 5:139.
- **Hansen HJ, Rorth M and Vindelev L (1991):**
Small cell lung cancer. In: Comprehensive textbook of oncology, vol. 1, second edition. Eds. by: Mossa AR, Schimpff SC and Robson MC. Published by Williams and Wilkins, Philadelphia.
- **Hansen M, Hammer M and Hammer L (1980a):**
ACTH, ADH and calcitonin concentrations as markers of response and relapse in small cell carcinoma of the lung.
Cancer, 46:2062.

- **Hansson L (1994):**
Comparison of two assays (TPA and TPS) for cytokeratin polypeptides in serum using the different patient groups and in healthy subjects (abstract): In: Klapdor R (ed). Proceeding 7th Humburg Symposium on Tumour Marker, Munchen. Zuckschwert Verlag.
- **Henderson RD, Boszko A and Van Nostrand AWP (1974):**
Pharyngeoesophageal dysphagia and recurrent laryngeal nerve palsy.
J. Thorac. Cardiovasc. Surg., 68:507.
- **Hendrix M, Seftor E, Chu Y, Seftor R, Nagle R and McDaniel K (1992):**
Coexpression of vimentin and keratins by human melanoma tumour cells: correlation with invasive and metastatic potential.
J. Natl. Cancer Inst., 84:165
- **Hirayama T (1981):**
Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan.
Br. Med. J., 282:733.

- **Hirsch FR, Osterlind K and Hansen III (1983):**
Prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the WHO.
Cancer, 50:214.
- **Hoffmann D and Wynder ELA (1971):**
A study of tobacco carcinogenesis. Tumour imitators, tumour accelerators, and tumour promoting activity of condensate fractions.
Cancer (Phila), 27:848.
- **Hoffmann D, Haley NJ and Brunnemann KD (1983):**
Cigarette side stream smoke: formation, analysis and model studies on the uptake by non-smokers. Presented at the U.S. Japan Meeting on New Etiology of Lung Cancer, Honolulu, March, 21.
- **Huang SB, Jong TSAI, Lin Chong and Wang JJH (1997):**
Comparison of cytokeratin fragment 19 (CYFRA21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Resp. Medicine, (91); 135

- **Hughes JM and Weil H (1986):**
Asbestos exposure: Quantitative assessment of risk.
Am. Rev. Resp. Dis., 133:5.
- **Inaba N, Fukazawa I, Ota Y, Nito A, Ijichi M, Sato T and Takamizawa H (1985):**
Tissue polypeptide antigen and cancer antigen 125 in pregnancy: these two cancer-related antigens are oncoplacental?
Acta. Obstet. Gynaecol. Jpn., 37:2139.
- **Inoue M, Inoue Y, Hirumatsu K and Ueda G (1985):**
The clinical value of tissue polypeptide antigen in patients with gynecological tumours.
Cancer, 55:2618.
- **International Agency for Research on Cancer. (1994):**
Monograph on the evaluation of the carcinogenic risk of chemicals to humans, tobacco smoking.
World Health Organization, Geneva.

- **Isacson S and Arden-Sanberg A (1977):**
TPA and cytology in cancer of the urinary bladder. Proceeding of a symposium on clinical application of carcinoembryonic antigen assay. Nice, France.
- **Itano M (1976):**
The detection of CPK1 (BB) in serum, a summary of sixteen cases
Am. J. Clin. Pathol., 65:351.
- **Jaques G, Auerbach B and Pritsch M (1993):**
Evaluation of serum neural cell adhesion molecule as a new tumour marker in small cell lung cancer.
Cancer, 72:418.
- **Jarvisalo J, Hakama M, Knekt P, Stenman U H, Leino A, Teppo L, Maatela J and Aromaa A (1993):**
Serum tumour markers CEA, CA50, TPST and NSE in lung cancer screening.
Cancer, 71:1982-1988.

- **Johnson BE, Ihde DC and Makuch RW ; (1987):**
Myc family oncogene amplification in tumour cell lines established from small cell lung cancer patients and its relationship to clinical status and course.
J. Clin. Invest., 79:1629.
- **Johnson PWM, Joel SP and Butcher M (1993):**
Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.
Br. J. Cancer, 67:760.
- **Johnston WW (1986):**
Cytologic diagnosis of lung cancer: Principles and problems. Pathol.
Res. Pract., 181:1.
- **Kakari S, Strngou E and Toumbis M (1991):**
Five tumour markers in lung cancer: Significance of total and "lipid" bound sialic acid.
Anti Cancer Research, 11:2107.

- **Kao CH, Gu CJ and Wang ST (1994):**
Tissue polypeptide antigen in hepatitis B carriers.
Anticancer Res., 14 (6B): 2817.
- **Kashiwabara K, Nakamura H and Kiguchi T (1998):**
Correlation between serum cytokeratin19 fragment and tissue polypeptide antigen levels in patients with NSCLC.
Clin. Chim. Acta, 31:149.
- **Kato K, Ariyoshi Y and Nakajama T (1985):**
Creatinine kinase B subunit as a biomarker for small cell carcinoma of the lung: Comparison with γ enolase.
Jpn. J. Cancer Res., 76:1162.
- **Katsima A, Miyaka Y and Urakami K (1995):**
Enzyme immunoassay of immunoreactive progestin-releasing peptide (31-98) as tumour marker for small cell lung carcinoma. Development and evaluation.
Clin. Chem., 41:537.

- **Kew MC and Berger EL (1986):**
The value of serum concentrations of tissue polypeptide antigen in the diagnosis of hepatocellular carcinoma.
Cancer, 58:127.
- **Khalifa A, Tash F, Gooma A (1992):**
Certain biochemical studies in intrathoracic malignancies. The 15th International Annual Ain Shams Medical Congress.
Ain Shams Faculty of Medicine, Cairo, Egypt.
21-24th Feb.
- **Khoo SK, Mackay IR (1973):**
CEA in serum in diseases of the liver and pancreas.
J. Clin. Path., 26:470.
- **Kjuns H, Skyaerven R and Langard S (1986):**
A case referent study of lung cancer. Occupational exposure and smoking: Role of asbestos exposure.
Scand J. Work, Environ. Health, 12:303.
- **Klee GG, Go VLW (1982):**
Serum tumour markers.
Mayo Clin. Proc., 57:129.

- **Kumar S, Wilson P, Breuchley P, Taylor G, Bjorklund B and Eklund G (1978):**
Frequent evaluation of tissue polypeptide antigen in the sera of workers exposed to bladder carcinogens.
Int. J. Cancer, 22(5): 542.
- **Lamar W, Woodard L and Statland BE (1978):**
Clinical implications of creatine kinase BB isoenzymes.
New Engl. J. of Med., 299:834.
- **Lamb D (1984):**
Histological classification of lung cancer.
Thorax, 39:161.
- **Land H, Grez M and Ruppert S (1983):**
Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor DNA.
Nature, 302:342.
- **Lang H and Wurzburg U (1982):**
Creatine kinase, an enzyme of many forms.
Clin. Chem., 28:1439.

- **Lannuzzi MC and Scoggin CH (1986):**
Small cell lung cancer.
Am. Rev. Respir. Dis., 134:593.
- **LeRoux BT (1968) Quoted from Harrison (1992):**
Bronchial carcinoma.
Thorax, 23:136.
- **Leube RE, Bosch FX, Romano V, Zimbelman R, Hofler H and Franke WW (1986):**
Cytokeratin expression in simple epithelia. III: Detection of mRNAs encoding human cytokeratins nos. 8 and 18 in normal and tumour cells by hybridization with cDNA sequences in vitro and in situ.
Differentiation, 33: 69.
- **Levin ML, Tockman MS and Frost JK (1982):**
Lung cancer mortality in males screened by chest X-ray and sputum examination: A preliminary report. Recent Results.
Cancer Res., 82:138.

- **Liu Q, Nap M and Oehr P (1991):**
The diagnostic significance of histological and serological tracing of TPA in cancer patients.
Tumor diagnosis Ther., 11:78
- **Liu Q, Nap M and Oehr P (1992):**
The immunohistochemical relation between keratin, TPA and TPS in human tissues. In: Klapdor I (ed). Tumour associated antigens oncogene, receptors, cytokines in tumour diagnosis and therapy at the beginning of the nineties. Cancer of the breast-state and trends in diagnosis and therapy: 517-21 W. Zuckschwaldt Verlag Munchen, Born, Wien, New York.
- **Loeb LA, Ernster VL and Warner KE (1984):**
Smoking and lung cancer: An Overview.
Cancer Res., 44:5940.
- **Lokich JJ (1982):**
The frequency and clinical biology of the ectopic hormone syndrome of small cell carcinoma.
Cancer, 50:2111.

- **Lokich JJ (1978):**
Tumour markers in malignant diseases.
Oncology, 35:54.
- **Lokich JJ and Goodman R (1975):**
Superior vena cava syndrome: Clinical
management.
JAMA, 231:58.
- **Loss U, Oehr P, Genske F and Schlack W (1988):**
Diagnostic value of the tumour markers CEA
and TPA in bronchoalveolar lavage fluid (ger).
Prox. Klin. Pneumol., 42 (suppl.1): 235.
- **Lunde OCH and Havig O (1982):**
Clinical significance of (CEA) in patients with
adenocarcinoma in colon & rectum.
Acta Chim. Scand., 148:189.
- **Luning B (1994):**
On the use of historical clinical data for TPA
(Letter to editor).
Clin. Chem., 40(8): 6:1607.

- **Luning B, Nilsson U, Luning M and Thuresson G (1984):**
What is TPA? (Tissue polypeptide antigen): On the relation between TPA and cytokeratins. In: Pecters, H. (ed). *Protides Biol Fluids Proc Colloq.*, 32: 717.
Pergamon Press Oxford.
- **Luning B, Wiklund B, Redelius P and Bjorklund B (1980):**
Biochemical properties of tissue polypeptide antigen. *Biochem. Biophys. Acta.*, 624(1): 90.
- **Lurie BB, Lowenstein MS and Zamcheck N (1975):**
Elevated (CEA) levels and biliary tract obstruction.
J. Am. Med. Assoc., 233:326.
- **Mack TM (1979):**
The evaluation of immunodiagnosis tests.
Br. Med. J., v:382.

- **Mansour O, Motowi T, Khaled H and El-Ahmady O (1993):**
Clinical value of thymidine kinase and tissue polypeptide antigen in breast cancer.
Dis. Markers, 11(4): 171.
- **Marel M and Svandova E (1991):**
Discrimination analysis in differential analysis of pleural effusions (ze).
Cas. Lek. Cesk., 130(16-17): 509.
- **Marrink J, Oosterom R, Bonfrer HM, Schroder FH and Mensink HJ (1993):**
Tissue polypeptide antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Eur. J. Cancer, 29A(4): 570.
- **Martin EWJ, Cooperman M, Carey LC and Minton JP (1980):**
Sixty second-look procedures indicated primarily by rise in serial (CEA).
J. Surg. Res., 28:389.

- **Mathews MJ and Gorden PR (1977):**
Morphology of pulmonary and pleural malignancies. In Strauss, M.J. (ed.) Lung cancer: Clinical diagnosis and treatment. New York, Grune and Stratton.
- **Mathews MJ, Kanahouwa S and Pickner J (1973):**
Frequency of residual and metastatic tumours in patients undergoing curative surgical resection of lung cancer.
Cancer Chemother. Rep., 3:63.
- **Matsushima M, Kuwabara T and Miyamae K (1984):**
Serum tissue polypeptide antigen in patients with urogenital cancer.
Hinyokika Kyo., 30:869 (English abstract).
- **Maulard C, Toubert ME, Chertien Y, Delanian S, Dufour B and Housset M (1994):**
Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumour marker. A prospective study.
Cancer, 73(2):394.

- **Maurer LH, O'Donnel JF and Kennedy S (1983):**
Human neurophysins in carcinoma of the lung: Relation to histology disease stage, survival and the syndrome of inappropriate antidiuretic hormone secretion.
Cancer Treat. Rep., 67:971.
- **McComb PB (1983):**
The measurement of lactate dehydrogenase. In: Clinical and Analytical Concepts in Enzymology. Homburger, H.A. Ed. Skokle, I.L. College of American Pathologists, pp. 157.
- **Mckenzie CG, Evans IM, and Hillyard CJ (1977):**
Biochemical markers in bronchial carcinoma.
Br. J. Cancer, 30:700.
- **Mellerick D, Osborn M and Weber K (1990):**
On the nature of serological TPA; monoclonal keratin 8, 18 and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum.
Oncogene, 5(7): 1007.

- **Memoli V and North WG (1987):**
A monoclonal antibody to human neurophysin recognizes pulmonary neuroendocrine carcinomas.
Lab. Invest., 56:509.
- **Menedez-Botet CJ, Oettgen HF, Pinsky CM and Schwartz MK (1978):**
A preliminary evaluation of TPA in serum or urine (or both) of patients with cancer or benign neoplasms.
Clin. Chem., 24:868.
- **Menedez V, Filella X, Alcover J, Molina R, Ballest AM and Carretero P (1995):**
Role of tissue polypeptide antigen as a marker in bladder cancer.
Acta. Urol. Esp., 19(6):441.
- **Micheal L, Bishop, Janet L, Duben-Engelkirk and Edward P (1996):**
Clinical Chemistry, 486.

- **Minna JD, Cuttitta F and Battey JF (1988):**
Gastrin-releasing peptide and other autocrine growth factors in lung cancer: Pathogenesis and treatment implications. In Devita VT, Hellman S and Rosenberg SA (eds). Important advances in Oncology. pp. 55. (ed): J.B. Lippincott, Philadelphia.
- **Minna JD, Pass H and Glastin E (1989):**
Cancer of the lung. In: Devita VT, Hellman S and Rosenberg SA Cancer: Principles and practice of oncology. pp. 590 (ed). JB Lippicott, Philadelphia.
- **Mino N, Iho D and Hamamoto K (1988):**
Availability of tumour-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs.
Cancer, 62:730.
- **Miyake Y, Yamahuchi K and Kodama T (1994):**
Pro-gastrin-releasing peptide (31-98) is a specific tumour marker in patients with small cell lung carcinoma.
Cancer Res., 54:2136.

- **Minna JD, Cuttitta F and Battey JF (1988):**
Gastrin-releasing peptide and other autocrine growth factors in lung cancer: Pathogenesis and treatment implications. In Devita VT, Hellman S and Rosenberg SA (eds). Important advances in Oncology. pp. 55. (ed): J.B. Lippincott, Philadelphia.
- **Minna JD, Pass H and Glastin E (1989):**
Cancer of the lung. In: Devita VT, Hellman S and Rosenberg SA Cancer: Principles and practice of oncology. pp. 590 (ed). JB Lippicott, Philadelphia.
- **Mino N, Iho D and Hamamoto K (1988):**
Availability of tumour-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs.
Cancer, 62:730.
- **Miyake Y, Yamahuchi K and Kodama T (1994):**
Pro-gastrin-releasing peptide (31-98) is a specific tumour marker in patients with small cell lung carcinoma.
Cancer Res., 54:2136.

- **Mizushima Y, Tsuji H, Izumi S, Hirata H and Yano S (1991):**
Clinical evaluation of five tumour marker assays in patients with lung cancer.
Anticancer Res., 11:91.
- **Moll R, Franke WW, Schiller DL, Geiger B and Krepler R (1982):**
The catalog of human cytokeratins: patterns of expression in normal epithelia, tumours and cultured cells.
Cell, 31:1.
- **Moll R, Schiller D and Franke WW (1990):**
Identification of protein 17 of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns.
J. Cell. Biol., 111:567.
- **Moll R, Franke W, Schiller DL, Geiger B and Krepler R (1982):**
The catalog of human cytokeratins: patterns expression in normal epithelia, tumours and cultured cells.
Cell, 31:11.

- **Morczynska A, Kulpa J, Lenko J and Augustin M (1988):**
Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
Int. Urol. Nephrol., 20:123.
- **Moses AM and Scheinman SJ (1991):**
Ectopic secretion of neurohypophyseal peptides in patients with malignancy.
Endocrinal Metab. Clin. N. Am., 20:489.
- **Moss DW and Henderson AR (1994):**
Enzymes in: Tietz Textbook of Clinical Chemistry, 2nd ed. vol. 2. Burtis CA and Ashwood ER (eds.).
WB Saunders Company, pp. 812.
- **Mountain CF (1986):**
A new international staging system for lung cancer.
Chest, 9:1.
- **Mross KB, Wolfrum DI and Rauschecker H (1985):**
Determination TPA levels in different cancer types and controls.
Oncology, 42:288.

- **Mulder H, Hackeng WH, and Silberbusch J (1981):**
Value of serum calcitonin estimation in clinical oncology.
Br. J. Cancer, 43:786.
- **Muller T, Marshall R, Watson D, Walker D and Means A (1985):**
The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis.
Eur. J. Cancer. Clin. Oncology, 12:1461.
- **National Institute of Health (1981):**
Carcinoembryonic antigen (CEA): its role as a marker in the management of lung cancer.
Br. Med. J., 282:373.
- **Nathrath W, Heidenkummer P, Bjorklund V and Bjorklund B (1985):**
Distribution of TPA in normal human tissues: immunohistochemical study on unfixed, methanol, ethanol and formalin fixed tissues.
J. Histochem. Cytochem., 33(2):99.

- **Nicolini A, Carpi A, DiMarco G, Giuliani L, Giordani R and Palla S (1989):**
A rational postoperative follow up with carcinoembryonic antigen, tissue polypeptide antigen and urinary hydroxyproline in breast cancer patients.
Cancer, 63:2037.
- **Nikliński J, Furman M and Polyncko Z (1991):**
Carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB as tumour markers for carcinoma of lung.
Neoplasma, 38:645.
- **Nisman B, Lafair J, Heching N and Baras M (1998):**
Evaluation of TPS, CYFRA21-1 and CEA in NSCLC.
Cancer, 15:1850.
- **North WG (1991):**
Neuropeptide production by small cell carcinoma: Vasopressin and oxytocin as plasma markers of disease.
J. Clin. Endocrinol. Metab., 73:1316.

- **North WG, Ware J and Maurer LH (1988):**
Neurophysins as tumour marker for small cell carcinoma of the lung.
Cancer, 62:1343.
- **Ochi Y, Ura Y, Hamazu H, Ishida M, Kajita Y and Nakajima Y (1985):**
Immunological study of tissue polypeptide antigen (TPA) demonstration of keratin-like sites and blood group antigen-like sites on TPA molecules.
Clin. Chem. Acta., 151:157.
- **Odel WD and Wolfsen AR (1978):**
Humaoral syndromes associated with cancer.
Ann. Rev. Med., 29:379.
- **Oehr P, Bellmann O and Hamann D (1982a):**
Measurement of Tennessee antigen, carcinoembryonic antigen, tissue polypeptide antigen and alpha-fetoprotein in body fluids associated with pregnancy.
Clin. Biochem., 15(1):13.
- **Oehr P, Luthgens ML and Lin Q (1992):**
Tissue polypeptide antigen and specific TPA. In: Serological cancer markers. Edited by Stewart S.
The Humana Press, Totowa, N.J.

- **Oehr P, Derigs G and Altmann R (1981):**
Evaluation and characterization of tumour-associated antigens by conversion of inverse distribution function values into specificity-sensitivity diagrams.
Tumour Diagnostik., 2(6):28.
- **Oehr P, Kersjes W, Kunath U, Biersack H.J, Sipeer U and Winkler C (1982b):**
Distribution, sensitivity and specificity of TPA, CEA and marker product values for patients with carcinoma of the gastrointestinal tract.
Tumour Diagn. Ther., 3(415):195.
- **Oehr P, Kramer M, Schult B, Vogel J and Rink H (1986):**
Mechanism of release of TPA to the circulation and its importance for the follow up of patients with carcinoma (ger). In: Wast G (ed). Tumour marker, Current aspects and clinical relevance. Proceeding for Symposium on Tumour Markers. Manster, W. Germany. Steinkopf, Darmstadt. pp: 65.

- **Oehr P, Liu Q, Schultes B, Lechmann M, Ota Y and Jin HY (1991):**
Serum concentrations of CEA, TAG and TPA with regard to stage, grade and course of disease in bladder carcinoma patients.
Tumour Diagnostic, 2(1): 27.
- **Panza N, Pacilio G and Campanella L (1988):**
Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.
Cancer, 61:76.
- **Pare PA and Fraser RG (1985):**
Neoplastic diseases of the lung.
First ed. W.B. Saunders Company. p.400.
- **Passanen PA, Eskelinen M, Pikkarainen P, Penttinen I and Alhava E (1994):**
Diagnostic value of tissue polypeptide antigen in patients with pancreatic carcinoma.
Tumour Biol., 15(1):52.
- **Paulson DL (1975):**
Carcinomas of the superior pulmonary sulcus.
J. Thorac. Cardiovasc. Surg., 70:1095.

- **Pedersen AG, Bach FW, Nissen M and Bach F (1985a):**
Creatine kinase BB and beta 2 microglobulin as markers of CNS metastases in patients with SCLC. *J. Clin. Oncol.*, 3:1364.
- **Pedersen AG, Becker K, Marangos P, Bach FW, Gazader A and Bunn P (1985b):**
Bombesin (BM), creatine kinase BB (CK-bb), Calcitonin (C) and (NSE) in the (CSF) as a marker of CNS metastases and meningeal carcinomatosis (MC) in (SCLC).
Am. Assoc. Cancer Res., 26:146.
- **Pedersen AG, Hammer M, Hansen M and Sorensen PS (1985c):**
CSF ADH as marker of CNS metastases from SCLC.
J. Clin. Oncol., 3:48.
- **Plebani M, Dasso D and Navaglia F (1995):**
Clinical evaluation of seven tumour markers in lung cancer diagnosis: Can any combination improve the results.
Br. J. Cancer, 72:170.

- **Plebani T, Cbiavacci A, Olmi P, Kunath U and Kersijes W (1989):**
Serum tissue polypeptide antigen in pancreatic cancer and other gastrointestinal diseases (Letter to editor).
J. Clin Pathol., 42:555.
- **Plebani M, Navaglia F, Basso D, Giacomini A and Burlina A (1994):**
Serum CYFRA 21-1 in the assessment of epithelial cancers.
J. Tumour Marker Oncol., 9:13.
- **Pohl AL (1987):**
Survillance of cancer patients with tumour markers.
J. Tumour Markers Oncology, 2(1):6.
- **Pujol JL, Cooper E, Grenier J, Purves D and Lehmann M (1994):**
Clinical evaluation of serum tissue polypeptide specific antigen (TPS) in NSCLC.
Eur. J. Cancer. 30A:1768.

- **Pujol JL, Grenier J, Daures JP, Daver A, Pujol H and Michel FB (1993):**
Serum fragment of cytokeratins subunit 19 measures by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Cancer Res., 53:61.
- **Rapellino M, Pecchino F and Baldi S (1995):**
Clinical utility of tissue polypeptide antigen determination in lung cancer management.
Int. J. Biol. Markers, 29:160.
- **Rastel D, Ramaioli A, Cornillie F and Thirion B (1994):**
Behave of the CYFRA21-1 multicentric study group. CYFRA21-1: a sensitive and specific new tumour marker for squamous cell lung cancer.
Eur. J. Cancer, 5:601
- **Kedelius P, Luning B and Bjorklund B (1980):**
Chemical studies on tissue polypeptide antigen (TPA). II. Partial amino acid sequence of cyanogen bromide fragment of TPA subunit B1.
Acta. Chem. Scand. B., 34:265.

- **Schrock R, Hafter R, Schmid L, Babic R, Ulm K, Gossner W and Graeff H (1986):**
 Tumour associated antigens and fibrin derivatives as reaction products of ovarian cancer (ger).
 Geburtshilfe Frauenheilkd., 46(1): 1.
- **Schultek T, Weissmann KJ, Braun J, Wood WG (1985):**
 Karzinoembryonales antigen (CEA) and tissue polypeptide antigen (TPA) in der diagnose des
 • Kleinzelligen and nicht-kleinzelligen bronchialkarzinoms.
 Prax Klin Pneumol. 39:962-66.
- **Schultek T and Wood WG (1985):**
 Tissue polypeptide antigen (TPA) as prognostic parameter in small-cell and non-small-cell bronchial carcinoma.
 Arztl Lab. 31:273-79.
- **Schwartz MK (1982):**
 Enzymes tests in cancer.
 Clin. Lab. Med., 2:479.

- **Seaton A, Seaton D and Leitch AG (1989):**
Cancer of the lung in: Crofton and Douglas's
respiratory diseases.
Vol. II, Fourth ed. Blackwell Scientific
Publications, Oxford.
- **Sell S (1992):**
Serological cancer markers.
Totawa, N.J., The Humana Press.
- **Sellers TA, Barky Wilson JE and Eloton EC
(1990):**
Evidence for mendelian inheritance in pathology
of lung cancer.
Natl. Cancer Inst., 82:1272.
- **Senekjian EK, Young JM and Weiser PA
(1987):**
An evaluation of squamous cell carcinoma
antigen with cervical squamous cell carcinoma.
Am. J. Obstet. Gynecol., 157:433.
- **Ślodka J, Szturmowicz M, Rudziński P,
Sakowicz A and Rosiuk W (1998):**
Expression of CEA and trophoblastic cell markers
by lung carcinoma in association with histological
characteristics and serum marker levels.
Eur. J. Cancer. Prev., 7(1):51.

- **Sobel RE, O'Connor DT and Addison I (1986):**
Elevated serum chromogranin A concentrations in small cell lung cancer.
Ann. Intern. Med., 105:698.
- **Speizer FE (1986):**
Overview of the risk of respiratory cancer from airborne contaminants.
Environ. Health Perspect., 70:9.
- **Spinazzi A, Soresi E, Boffi R, Nonis A, Nosedà A, Cobelli S and Scanni A (1994):**
Evaluation of neuron-specific enolase, tissue polypeptide antigen and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Cancer Detect. Prev., 18(3): 209.
- **Stahle E, Glimelius B, Bergstrom R and Pahlman L (1988):**
Preoperative serum markers in carcinoma of the rectum and rectosigmoid I. Prediction of tumour stage.
Eur. J. Surg. Oncol., 14:287.

- **Steiber P, Hasholzner U and Bodenmuller H (1993):**
Cyfra 21-1: A new marker in lung cancer.
Cancer, 72:707.
- **Steinart PM and Roop DR (1988):**
Molecular and cellular biology of intermediate filaments.
Annu. Rev. Biochem., 57:593.
- **Stieber P, Hasholzner U and Patch-Moghadam A (1993):**
CYFRA 21-1. A new marker in lung cancer.
Cancer, 72:707.
- **Tager IB, Weiss ST and Munoz A (1983):**
Longitudinal study of the effects of maternal smoking on pulmonary function in children.
N. Engl. J. Med., 309:699.
- **Takada M, Masuda N and Matsuura E (1995):**
Measurement of cytokeratin 19 fragments as a marker of lung cancer by cyfra 21-1 enzyme immunoassay.
Br. J. Cancer, 71:160.

- **Tal M and Halperin H (1970):**
TPA-RIA in clinical cancer diagnostics. In: Peeters, H. (ed). Protides of the biological fluids. Oxford: Pergamon Press; 263.
- **Tarle M (1993):**
Serial measurements of tissue polypeptide antigen (TPA), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. Anticancer Res., 13(3):769.
- **Tokuyama T, Yonada T and Hamada K (1995):**
Diagnostic value of tissue polypeptide antigen in pleural effusion with malignant pleural mesothelioma. Nippon-Kyobu-Shikkan-Gakkai-Zasshi., 33(1):39.
- **Tormy DC, Daris TE and Walkes TP (1982):**
Tumour markers in: Carter, S.K. and Livingstone, R.B. (eds.) Principles of cancer treatment. McGraw-Hill, New York.

- **Tozuka K, Yonese Y, Nakagami Y, Toshihisa H, Iiedo N and Masao T (1984):**
Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer (English abstract).
Gan. Tokagaku. Ryoho., 11:1078.

- **Tsung SW (1976):**
Creatine kinase isoenzyme patterns in human tissue obtained at surgery.
Clin. Chem., 22:137.

- **Turner-Warwick M, Lebowitz M and Johnson A (1980):**
Cryptogenic fibrosing alveolitis and lung cancer.
Thorax, 35:496.

- **U.S. Dept. of Health and Human Services (1992):**
- Smoking and health in Americans. National cancer for chronic disease prevention and health promotion office on smoking.
DHHS publication (CDC), 92:84.

- **Uhlenbruck G, Hamish FG, Vierbuchen M and Dienst C (1987):**
 Biochemistry and histo chemistry of new tumour markers (CA 125, CA 19-9, CA 50): Relationship to blood groups antigens (Inductory Lecutres).
 New tumour marker and thin monoclonal antibodies.
- **United States Public Health Service (1982):**
 The health consequences of smoking-cancer. A report of the Surgeon General. Rockville, M.D.: United States Department of Health and Human Services. Office of Smoking and Health.
- **United States Public Health Service (1964):**
 Smoking and Health. Report of the advisory Committee of the Surgeon General of Public Health Service. United States Department of Health, Education, and Welfare, Center for Disease Control.
- **Van der Gaast A, Schoenmakers CHH and Splinter TAW (1994):**
 Evaluation of a new tumour marker in patients with non-small cell lung cancer; CYFRA 21-1. Br. J. Cancer, 69:525.

- **Van der Gaast A, W.I.j. Van P and Kozijnsen R (1991):**

Prognostic value of serum thymidine kinase, TPA and NSE in patients with SCLC.
Br. J. Cancer, 64:369.

- **Volpino P, Cangemi V, Caputo V (1985):**
Clinical usefulness of serum TPA (tissue polypeptide antigen) in postsurgical diagnosis, prognosis, and follow-up of lung cancer.
J. Nucl. Med. Allied. Sci. 29:241-44.

- **Waldman TA and Heberman RB (1982):**
Tumour markers in diagnosis and monitoring therapy. In: Holland, L.F.:
Cancer Medicine, Second Edition, eds: Lea and Febiger, Philadelphia.

- **Walz, Kunzendorf U and Josimovic-Alasevic O (1990):**
Soluble Interleukin 2 receptor and tissue polypeptide antigen serum concentration in end-stage renal failure.
Nephron, 56(2):157.

- **Wanebo HJ, Rao B and Pinsky CM (1978):**
Preoperative CEA level as a prognostic indicator in colorectal cancer.
N. Engl. J. Med., 299:448.
- **Wang JY, Tang R and Chiang JM (1994):**
Value of (CEA) in the management of colorectal cancer.
Dis. Colon Rectum, 37:272.
- **Wawzynczak EJ (1991):**
Systemic immunotoxin therapy of cancer: Advances and prospects.
Br. J. Cancer, 64:624.
- **Webb Wr, Jensen BG and Svelluto R (1985):**
Bronchogenic carcinoma: Staging with MRI compared with staging with CT and surgery.
Radiology, 156:117.
- **Weber K, Osborn M, Moll R, Wiklund B and Luning B (1984):**
Tissue polypeptide antigen (TPA) is related to the non epidermal keratins 8, 18 and 19 typical of simple and non squamous epithelia: Re-evaluation of a human tumour marker.
EMBO. J., 3:2707.

- **Weisbord GL (1987):**
Percutaneous fine needle aspiration biopsy of the mediastinum.
Clin. Chest Med., 8:27.
- **Whitley RJ, Meikle AW and Watts NB (1994):**
Protein hormones. In: Teitz Textbook of Clinical Chemistry. Burtis, C.A. and Ashwood, E.R. 2nd ed. Published by Saunders Company, P.1676.
- **Wiklund B, Silen A, Nilsson S and Andersson EL (1994):**
Monoclonal TPA cyk assays quantifying human cytokeratin 8 and 18 fragments in serum of cancer patients. In: Klapdor, R. (ed). Current Tumour Diagnosis: Applications, clinical relevance, research, trends. Cancer of the lung-state and trends in diagnosis and therapy. Zuckschwerdt, Munchen, Bern-Wien New York, pp: 50.

- **Willsher PC, Beaver J, Blamey RW and Robertson JF (1995):**
Serum tissue polypeptide antigen (TPA) in breast cancer patients: comparison with CA 15.3 and CEA.
Anticancer Res., 15(4): 1609.
- **Yamaguchi K, Abe K and Kameya T (1983):**
Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumours.
Cancer Res., 43:3932.
- **Yamaguchi K, Abe K and Adachi I (1986):**
Peptide hormone production in small cell lung carcinoma with particular reference to gastrin-releasing peptide.
J. Clin. Oncol., 16:235.